Form 4: Kalaris Therapeutics Director, Leone D Patterson, Acquires 18,000 Stock Options

Director Leone D Patterson acquired 18,000 stock options in Kalaris Therapeutics, Inc. on April 10, 2025, according to a Form 4 filing.

Summary

• Leone D Patterson, a director of Kalaris Therapeutics, Inc., filed a Form 4 indicating a change in beneficial ownership.
• On April 10, 2025, Patterson acquired 18,000 stock options with an exercise price of $7.31.
• These options vest in equal monthly installments over three years, from April 3, 2025, to April 3, 2028, contingent upon continuous service.
• Following the transaction, Patterson directly owns 18,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director suggests confidence in the company, but it's a routine transaction.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals insider confidence.

Key Dates

Keywords

Kalaris Therapeutics, Stock Options, Form 4, Beneficial Ownership, Director, Patterson, KLRS